Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Personalis (PSNL) stock in plain English

Free brief · no signupStart here
PSNLPublished Nov 19, 2026
Personalis Inc
Healthcare · Diagnostics & Research
Sells genomic sequencing assays to pharmaceutical companies and medical research centers running oncology clinical trials.
Assets:
Fremont laboratoryHigh-throughput clinical sequencing center in California
NeXT PersonalCustom liquid biopsy platform detecting residual disease
Tempus commercial partnershipCo-exclusive diagnostic sales agreement across US oncology clinics
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

55
OPS ScoreOperating finances
Latest quote
-1.74%$14.72
$1.60B
n/a (loss)
$80.75M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was PSNL. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Personalis (PSNL) do?

Personalis Inc (PSNL) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells genomic sequencing assays to pharmaceutical companies and medical research centers running oncology clinical trials. Analyzes whole human genomes and transcriptomes from tissue and blood to guide targeted cancer therapies. It is worth $1.60B on the market and sold $80.75M over the last year.

Market cap
$1.60B
P/E ratio
None (reported a loss)
Annual sales
$80.75M
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 19, 2026

Brands and businesses behind PSNL

  • NeXT Personal: Personalized liquid biopsy assay sold to monitor cancer recurrence from blood samples.
  • Immunidex: Diagnostic assay sold to pharmaceutical developers to measure patient immune system activity during immunotherapy trials.

PSNL’s flags, in plain English

Each flag is a number from Personalis’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Stupid Cash

Can pay this year's bills 4.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Insiders Hold

Insiders own 32.6% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.

Low debt

Low debt, only 17% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Burning Cash

Losing money, profit margin of -147.7%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about PSNL

How big is Personalis?

Personalis’ market cap is $1.60B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $80.75M: what customers paid the company over the last year, before any costs.

What is PSNL’s P/E ratio?

PSNL has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.

What could go wrong with PSNL?

The company generates substantial net cash losses and depends on external financing or licensing agreements to fund operations. That is one risk on Personalis’ card. Its first risk flag is Burning Cash, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Personalis’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PSNL’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card